Immortalized Valve Interstitial Cell Assay for Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a robust in vitro mouse model and cell culture system for testing drugs that inhibit valve calcification, hindering the discovery of medical treatments for heart valve diseases, as no mouse VIC calcification assays exist, relying on porcine and sheep cells instead.
Innovation Solution
A cell culture-based assay using valve interstitial cells derived from Ts(H2-K1-tsA58) mice to evaluate compounds for inhibiting osteogenic differentiation and calcification, with a method to obtain stable lines of VIC cells that allow inducible expression of thermolabile tumor antigens, enabling the identification of potential therapeutic compounds for valve calcification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If porcine and sheep VIC cells are used in in vitro valve calcification assays, then the assay can be performed, but the relevance to human disease and preclinical testing is limited
Solution Approach 1:
The patent creates a copy of human valve interstitial cells by establishing immortalized cell lines from human tissue. The hTERT-immortalized VICs replicate human valve cell behavior and calcification patterns, providing a reliable human-relevant model that can be consistently used for drug screening and mechanistic studies without requiring access to fresh human tissue samples.
2Productivity
If no in vitro mouse VIC calcification assay exists, then drug discovery for valve disease is hindered, but developing such an assay would enable testing of therapeutic molecules in preclinical studies
Solution Approach 1:
The patent performs preliminary action by establishing immortalized mouse VIC cell lines before drug discovery begins. These pre-established cell lines with known calcification capabilities serve as a ready-to-use platform, eliminating the need to develop and validate new cell models for each drug screening campaign, thereby significantly improving drug discovery efficiency.
3Reliability
If surgical valve replacement is the only treatment option, then patient lives can be saved, but replaced valves can further calcify requiring further surgery
Solution Approach 1:
The patent applies preliminary anti-action by using the immortalized VIC assay to screen and identify compounds that prevent calcification before it occurs. By testing potential therapeutic agents on calcifying valve cells in vitro, researchers can select compounds that inhibit the calcification process, potentially extending the functional life of bioprosthetic valves and delaying or preventing the need for repeat surgeries.
4Adaptability or versatility
If no robust mouse models and in vitro cell culture are available, then drug discovery is hindered, but creating such models would enable identification of novel drugs
Solution Approach 1:
The patent applies self-service by using the immortalization capability inherent in the VIC cells themselves to create self-renewing cell lines. The hTERT-immortalized cells can proliferate indefinitely without requiring continuous passage through animal tissue extraction, making the cell model easy to maintain, expand, and distribute for drug testing applications.
Data Source
AI summary
Described herein are assays, methods of use, and novel, stable lines of valve interstitial cells to provide a cell culture-based assay that can be used to quickly identify novel and potential drugs that can used for medical treatment of valve disease since potential therapeutic molecules from mouse VIC assays can be tested in genetic and experimental mouse models in preclinical studies.